Skip to content
DKBmed Radio

DKBmed Radio

DKBmed Podcasts – Medical Education Podcasts

Tag: dapagliflozin

Posted on October 29, 2015May 7, 2020

Beyond Basal Insulin: GLP-1 Receptor Agonists in Combination

Volume 2, Issue 3.

Kathleen Dungan, MD, MPH covers the important topic of GLP-1 Receptor Agonists in Combination in the format of case-study scenarios for the clinical practice.

http://media.blubrry.com/ediabetesreview/p/ediabetesreview.org/podcasts/audio/47-2-3.mp3

Podcast (ediabetes): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on September 2, 2015May 7, 2020

2015 ADA AND AACE CONFERENCE HIGHLIGHTS – Part 2

Volume 2, Issue 1 – Part  2.

Kathleen Dungan, MD, MPH from The Ohio State University interviews Dr. Jennifer Green from Duke University Medical Center about the TECOS study.

http://media.blubrry.com/ediabetesreview/p/ediabetesreview.org/podcasts/audio/47-2-1-2.mp3

Podcast (ediabetes): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on September 2, 2015May 7, 2020

2015 ADA AND AACE CONFERENCE HIGHLIGHTS – Part 1

Volume 2, Issue 1 – Part  1.

Kathleen Dungan, MD, MPH from The Ohio State University interviews Dr. Andrew Ahmann from the Oregon Health and Science University about the FLAT-SUGAR trial.

http://media.blubrry.com/ediabetesreview/p/ediabetesreview.org/podcasts/audio/47-2-1-1.mp3

Podcast (ediabetes): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Channels

  • DKBmed Radio
  • eCysticFibrosis Review
  • eDiabetes Review
  • eHIV Review
  • eMultipleSclerosis Review
  • ePrimaryCare Review
  • ePulmonology Review
  • eViralHepatitis Review
  • Start HCV
  • Start HIV

Recent Posts

  • UPDATE 10/30/2020 – Critically Ill Patients Part 1
  • UPDATE 10/28/2020 – COVID & HIV Part 1
  • UPDATE 10/23/2020 – Bone Marrow Transplants Part 2
  • UPDATE 10/21/2020 – COVID-19: State of Testing
  • Clinical Decisions: Selecting the Right Disease Modifying Therapy

Recent Comments

    Archives

    • linkedin
    • Facebook
    • Twitter
    • YouTube
    • RSS